Stocks Health care VTAK
NYSE · Health careCatheter Precision, Inc. (VTAK)
Catheter Precision, Inc. brought in $1.9M of revenue over the twelve months to June 30, 2026, up 219.2% from a year earlier. It posted a net loss of $13M. In fiscal 2025 capital spending exceeded operating cash flow by $8.3M. At June 30, 2026 it held $643K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about Catheter Precision, Inc.
- Net worth
- Catheter Precision, Inc. has a market value (market cap) of $2.2M at the latest share price, and shareholders' equity of $17.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $819K (+95.0% year on year), with a net loss of $17.2M. Over the 12 months to June 30, 2026: revenue $1.9M, net loss $13M.
- Cash flow
- In fiscal 2025 operations used $8.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
What Catheter Precision, Inc. does
Catheter Precision, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NYSE under the ticker VTAK.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $819K | -$17.2M | -$15.90 | -$8.3M |
| 2024 | $420K | -$16.6M | -$126.91 | -$9.3M |
| 2023 | $442K | -$70.6M | -$2,467.53 | -$20.7M |
| 2022 | $14K | -$26.9M | -$493.58 | -$22.6M |
| 2021 | $22K | -$25.1M | -$4,715.81 | -$27.9M |
| 2020 | $4.4M | -$36M | -$20,175.29 | -$28.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where VTAK ranks in Health care
Latest SEC filings
What Catheter Precision, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 5, 2026
- October 2, 2026Executive or director change8-KCatheter Precision announces a name change to Flyte Aviation, a 1-for-10 reverse stock split, and stockholder approval of all annual meeting proposals.
- September 25, 2026Other event 8-K
- August 31, 2026Proxy statement DEF 14A
- August 21, 2026Preliminary proxy statement PRE 14A
- August 21, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 381% to $1M versus the same quarter last year; diluted EPS -$0.92 versus -$7.28.
- July 31, 2026
- July 29, 2026Exhibits 8-K/A
- July 20, 2026Passive stake (5% or more) SCHEDULE 13G
Insider trades
What the people running Catheter Precision, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| December 5, 2025 | Jenkins David AChairman of the Board and CEO | Exercised options | 12,064 | - |
| December 5, 2025 | Jenkins David AChairman of the Board and CEO | Exercised optionsindirect | 30,844 | - |
| December 5, 2025 | Jenkins David AChairman of the Board and CEO | Exercised optionsindirect | 98 | - |
| December 5, 2025 | Caruso James JosephDirector | Exercised options | 41 | - |
Who owns VTAK
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| C/M Capital Partners, LP13G, passive with 4 related filers | 9.99% | August 21, 2026 |
| Jenkins Casey A.13D, may seek influence with 1 related filers | 9.9% | January 3, 2025 |
| Seg Jets Spv I, LLC13G, passive | 9.79% | July 20, 2026 |
| Catheter Precision, Inc.13G, passive | 7.5% | June 26, 2026 |
| Gregory Castaldo13G, passive | 7.5% | February 11, 2026 |
| Joseph Reda13G, passive | 7.5% | February 11, 2026 |
Largest institutional holders
Insiders
2 insiders reported holding 13,958 shares in total, about $2.1K at the last price.
| Holder | Shares |
|---|---|
| Jenkins David AChairman of the Board and CEO | 13,908109 held indirectly |
| Caruso James JosephDirector | 50 |
Questions about VTAK
What does Catheter Precision, Inc. do?
Catheter Precision, Inc. is a company in the Health care sector, listed on NYSE as VTAK. Its shares trade on NYSE under the ticker VTAK.
What is Catheter Precision, Inc.'s net worth?
Catheter Precision, Inc. has a market value (market cap) of $2.2M at the latest share price, and shareholders' equity of $17.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Catheter Precision, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $13M on revenue of $1.9M.
How much revenue does Catheter Precision, Inc. make?
Over the twelve months to June 30, 2026 Catheter Precision, Inc. reported revenue of $1.9M. That is 219.2% more than a year earlier.
When did Catheter Precision, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from October 5, 2026.
Similar companies
Compare VTAK with
Follow VTAK
Get an email when Catheter Precision, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Catheter Precision, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.